Key features and details | |
Cat. No. | MABL-3555 |
Name | Anti-Spike protein (RBD) mabs |
Clone No. | Sb#15 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | grating-coupledinterferometry, inhibition, therapeutics, ELISA |
Species Reactivity | SARSCoronavirus2 (SARS-Cov-2) |
Basic Information | |
Specificity | This antibody recognizes and binds the SARS CoV 2 C-terminal receptor binding domain (RBD) located in the extracellular portion of the spike protein. |
Alternative Name | Receptor Binding Domain; SARS CoV 2 S glycoprotein; Sb15; COVID-19 Spike protein; RBD; Receptor Binding Domain; E2 glycoprotein; E2; Human coronavirus 2 spike glycoprotein; Peplomer protein; S glycoprotein; SARS coronavirus 2 S protein; SARS coronavirus 2 Spike Protein; SARS CoV 2 Spike protein; SARS CoV 2; SARS-CoV-2 S protein; SARSCoV2; SARS-COV-2 S protein; SARS-COV-2 Spike glycoprotein; SARSCOV2 Spike protein; Severe acute respiratory syndrome 2 spike glycoprotein; Severe acute respiratory syndrome virus 2 spike glycoprotein; Spike glycoprotein; 2019-nCoV; SARS-CoV2 |
UniProt | P0DTC2 |
Immunogen | This clone was originally isolated in a form of a synthetic nanobody (sybody) via a 'target swap' selection procedure against RBD-vYFP using ribosomal display and against RBD-Fc fusion during phage display rounds. |
Application Notes | This antibody is recommended for detection of SARS CoV 2 or 2019-nCoV. Its high specificity to the novel coronavirus was confirmed via ELISA testing (Walter et al., 2020). Furthermore, grating-coupled interferometry demonstrated that this antibody binds the receptor binding domain (RBD) of the spike protein with high affinity (Walter et al., 2020). Subsequent testing showed that this clone exhibits exceptionally strong inhibition of binding of SARS-Cov-2 RBD to hACE2, which is the receptor for the virus (signal of RBD association with hACE2 decreased over 90%) (Walter et al., 2020). This clone binds to a non- overlapping epitope relative to S#68 (Ab02017) what can be used in develoepment of anti-Covid-19 therapuetics granting together increased avidity to the spike protein (Walter et al., 2020). |
Antibody First Published | Walter et al. Sybodies targeting the SARS-CoV-2 receptor-binding domain BioRxiv (2020) |
Note on publication | Describes the generation and characterization of the antibody. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
